{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T15:56:41Z","timestamp":1777305401924,"version":"3.51.4"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T00:00:00Z","timestamp":1645401600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T00:00:00Z","timestamp":1645401600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1007\/s10067-022-06113-2","type":"journal-article","created":{"date-parts":[[2022,2,22]],"date-time":"2022-02-22T10:02:59Z","timestamp":1645524179000},"page":"2225-2231","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Tofacitinib combined with leflunomide for treatment of psoriatic arthritis with IgA nephropathy: a case report with literature review"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3422-1034","authenticated-orcid":false,"given":"Huifang","family":"Xue","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1755-761X","authenticated-orcid":false,"given":"Xin","family":"Ci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3081-2793","authenticated-orcid":false,"given":"Manyu","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3813-822X","authenticated-orcid":false,"given":"Lijun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7289-941X","authenticated-orcid":false,"given":"Xinru","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6306-8190","authenticated-orcid":false,"given":"Lin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0380-2477","authenticated-orcid":false,"given":"Xuehong","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,2,21]]},"reference":[{"key":"6113_CR1","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.jaad.2018.06.057","volume":"80","author":"SB Kaushik","year":"2019","unstructured":"Kaushik SB, Lebwohl MG (2019) Psoriasis: which therapy for which patient psoriasis comorbidities and preferred systemic agents. J Am Acad Dermatol 80:27\u201340","journal-title":"J Am Acad Dermatol"},{"key":"6113_CR2","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.jaad.2018.06.027","volume":"80","author":"F Alinaghi","year":"2019","unstructured":"Alinaghi F, Calov M, Kristensen LE, Gladman DD, Coates LC, Jullien D et al (2019) Prevalence of psoriatic arthritis in patients with psoriasis: a systematic review and meta-analysis of observational and clinical studies. J Am Acad Dermatol 80:251\u201365.e19","journal-title":"J Am Acad Dermatol"},{"key":"6113_CR3","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1111\/bjd.14961","volume":"176","author":"SK Grewal","year":"2017","unstructured":"Grewal SK, Wan J, Denburg MR, Shin DB, Takeshita J, Gelfand JM (2017) The risk of IgA nephropathy and glomerular disease in patients with psoriasis: a population-based cohort study. Br J Dermatol 176:1366\u20131369","journal-title":"Br J Dermatol"},{"key":"6113_CR4","doi-asserted-by":"publisher","first-page":"3620","DOI":"10.1093\/ndt\/gfp441","volume":"24","author":"J Barratt","year":"2009","unstructured":"Barratt J, Eitner F, Feehally J, Floege J (2009) Immune complex formation in IgA nephropathy: a case of the \u2018right\u2019 antibodies in the \u2018wrong\u2019 place at the \u2018wrong\u2019 time? Nephrol Dial Transpl 24:3620\u20133623","journal-title":"Nephrol Dial Transpl"},{"key":"6113_CR5","doi-asserted-by":"publisher","first-page":"2665","DOI":"10.1002\/art.21972","volume":"54","author":"W Taylor","year":"2006","unstructured":"Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H (2006) Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 54:2665\u20132673","journal-title":"Arthritis Rheum"},{"key":"6113_CR6","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s13555-019-00347-w","volume":"10","author":"A Kvist-Hansen","year":"2020","unstructured":"Kvist-Hansen A, Hansen PR, Skov L (2020) Systemic treatment of psoriasis with JAK inhibitors: a review. Dermatol Ther (Heidelb) 10:29\u201342","journal-title":"Dermatol Ther (Heidelb)"},{"key":"6113_CR7","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.semnephrol.2018.05.016","volume":"38","author":"J Novak","year":"2018","unstructured":"Novak J, Barratt J, Julian BA, Renfrow MB (2018) Aberrant glycosylation of the IgA1 molecule in IgA nephropathy. Semin Nephrol 38:461\u2013476","journal-title":"Semin Nephrol"},{"key":"6113_CR8","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1002\/ddr.21263","volume":"76","author":"T Torres","year":"2015","unstructured":"Torres T, Filipe P (2015) Small molecules in the treatment of psoriasis. Drug Develop Res 76:215\u2013227","journal-title":"Drug Develop Res"},{"key":"6113_CR9","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1111\/1346-8138.13258","volume":"43","author":"A Asahina","year":"2016","unstructured":"Asahina A, Etoh T, Igarashi A, Imafuku S, Saeki H, Shibasaki Y et al (2016) Oral tofacitinib efficacy, safety and tolerability in Japanese patients with moderate to severe plaque psoriasis and psoriatic arthritis: a randomized, double-blind, phase 3 study. J Dermatol 43:869\u2013880","journal-title":"J Dermatol"},{"key":"6113_CR10","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1016\/j.jaci.2015.12.1318","volume":"137","author":"J Krueger","year":"2016","unstructured":"Krueger J, Clark JD, Su\u00e1rez-Fari\u00f1as M, Fuentes-Duculan J, Cueto I, Wang CQ et al (2016) Tofacitinib attenuates pathologic immune pathways in patients with psoriasis: a randomized phase 2 study. Journal of Allergy and Clinical Immunology 137:1079\u20131090","journal-title":"Journal of Allergy and Clinical Immunology"},{"key":"6113_CR11","doi-asserted-by":"crossref","unstructured":"Ravipati A, Nolan S, Alphonse M, Dikeman D, Youn C, Wang Y, et al. (2021) IL-6R\/signal transducer and activator of transcription 3 signaling in keratinocytes rather than in T cells induces psoriasis-like dermatitis in mice. J Investig Dermatol","DOI":"10.1016\/j.jid.2021.09.012"},{"key":"6113_CR12","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1136\/ard.2008.096743","volume":"68","author":"I Gonz\u00e1lez-Alvaro","year":"2009","unstructured":"Gonz\u00e1lez-Alvaro I, Ortiz AM, Dom\u00ednguez-Jim\u00e9nez C, Arag\u00f3n-Bodi A, D\u00edaz S\u00e1nchez B, S\u00e1nchez-Madrid F (2009) Inhibition of tumour necrosis factor and IL-17 production by leflunomide involves the JAK\/STAT pathway. Ann Rheum Dis 68:1644\u20131650","journal-title":"Ann Rheum Dis"},{"key":"6113_CR13","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1016\/j.ekir.2017.07.002","volume":"2","author":"K Yamada","year":"2017","unstructured":"Yamada K, Huang ZQ, Raska M, Reily C, Anderson JC, Suzuki H et al (2017) Inhibition of STAT3 signaling reduces IgA1 autoantigen production in IgA nephropathy. Kidney Int Rep 2:1194\u20131207","journal-title":"Kidney Int Rep"},{"key":"6113_CR14","doi-asserted-by":"publisher","first-page":"973","DOI":"10.2215\/CJN.11010919","volume":"15","author":"J Tao","year":"2020","unstructured":"Tao J, Mariani L, Eddy S, Maecker H, Kambham N, Mehta K et al (2020) JAK-STAT activity in peripheral blood cells and kidney tissue in IgA Nephropathy. Clin J Am Soc Nephrol 15:973\u2013982","journal-title":"Clin J Am Soc Nephrol"},{"key":"6113_CR15","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/j.kint.2018.05.022","volume":"94","author":"J Tao","year":"2018","unstructured":"Tao J, Mariani L, Eddy S, Maecker H, Kambham N, Mehta K et al (2018) JAK-STAT signaling is activated in the kidney and peripheral blood cells of patients with focal segmental glomerulosclerosis. Kidney Int 94:795\u2013808","journal-title":"Kidney Int"},{"key":"6113_CR16","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1038\/ki.2013.197","volume":"84","author":"Y Dai","year":"2013","unstructured":"Dai Y, Gu L, Yuan W, Yu Q, Ni Z, Ross MJ et al (2013) Podocyte-specific deletion of signal transducer and activator of transcription 3 attenuates nephrotoxic serum\u2013induced glomerulonephritis. Kidney Int 84:950\u2013961","journal-title":"Kidney Int"},{"key":"6113_CR17","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1111\/1756-185X.13477","volume":"22","author":"Q Dai","year":"2019","unstructured":"Dai Q, Xu L, Yu X (2019) Efficacy and safety of leflunomide in psoriatic arthritis treatment: a single-arm meta-analysis. Int J Rheum Dis 22:1498\u20131505","journal-title":"Int J Rheum Dis"},{"key":"6113_CR18","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1002\/art.20253","volume":"50","author":"JP Kaltwasser","year":"2004","unstructured":"Kaltwasser JP, Nash P, Gladman D, Rosen CF, Behrens F, Jones P et al (2004) Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum 50:1939\u20131950","journal-title":"Arthritis Rheum"},{"key":"6113_CR19","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.3899\/jrheum.201408","volume":"48","author":"M Haroon","year":"2021","unstructured":"Haroon M, Batool S, Asif S, Hashmi F, Ullah S (2021) Combination of methotrexate and leflunomide is safe and has good drug retention among patients with psoriatic arthritis. J Rheumatol 48:1624\u20131626","journal-title":"J Rheumatol"},{"key":"6113_CR20","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1007\/s11255-019-02255-6","volume":"51","author":"J Yi","year":"2019","unstructured":"Yi J, He Z, Xu S, Feng S (2019) Efficacy and safety of leflunomide in IgA nephropathy: a systematic review and meta-analysis. Int Urol Nephrol 51:1987\u20131998","journal-title":"Int Urol Nephrol"},{"key":"6113_CR21","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1681\/ASN.2016040433","volume":"28","author":"M Haas","year":"2017","unstructured":"Haas M, Verhave JC, Liu Z-H, Alpers CE, Barratt J, Becker JU et al (2017) A multicenter study of the predictive value of crescents in IgA nephropathy. J Am Soc Nephrol 28:691\u2013701","journal-title":"J Am Soc Nephrol"},{"key":"6113_CR22","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1056\/NEJMoa1415463","volume":"373","author":"T Rauen","year":"2015","unstructured":"Rauen T, Eitner F, Fitzner C, Sommerer C, Zeier M, Otte B et al (2015) Intensive supportive care plus immunosuppression in IgA nephropathy. N Engl J Med 373:2225\u20132236","journal-title":"N Engl J Med"},{"key":"6113_CR23","doi-asserted-by":"publisher","first-page":"97","DOI":"10.2147\/PTT.S161453","volume":"9","author":"K Ly","year":"2019","unstructured":"Ly K, Beck KM, Smith MP, Orbai AM, Liao W (2019) Tofacitinib in the management of active psoriatic arthritis: patient selection and perspectives. Psoriasis-Targets Th 9:97\u2013107","journal-title":"Psoriasis-Targets Th"},{"key":"6113_CR24","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1111\/bjd.13551","volume":"172","author":"R Bissonnette","year":"2015","unstructured":"Bissonnette R, Iversen L, Sofen H, Griffiths CEM, Foley P, Romiti R et al (2015) Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: a randomized controlled trial. Brit J Dermatol 172:1395\u20131406","journal-title":"Brit J Dermatol"},{"key":"6113_CR25","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1016\/S0140-6736(20)30800-X","volume":"395","author":"ML Hetland","year":"2020","unstructured":"Hetland ML (2020) Psoriatic arthritis: still room for improvement. Lancet 395:1463\u20131465","journal-title":"Lancet"},{"key":"6113_CR26","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.2169\/internalmedicine.54.3510","volume":"54","author":"T Kaneko","year":"2015","unstructured":"Kaneko T, Mii A, Fukui M, Nagahama K, Shimizu A, Tsuruoka S (2015) IgA nephropathy and psoriatic arthritis that improved with steroid pulse therapy and mizoribine in combination with treatment for chronic tonsillitis and epipharyngitis. Intern Med 54:1085\u20131090","journal-title":"Intern Med"},{"key":"6113_CR27","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1007\/s10067-006-0422-z","volume":"26","author":"GT Sakellariou","year":"2007","unstructured":"Sakellariou GT, Vounotrypidis P, Berberidis C (2007) Infliximab treatment in two patients with psoriatic arthritis and secondary IgA nephropathy. Clin Rheumatol 26:1132\u20131133","journal-title":"Clin Rheumatol"},{"key":"6113_CR28","doi-asserted-by":"crossref","unstructured":"Garces CC, Hernandez Garcilazo N, Sharma A, Nader G. (2021) Severe psoriasis presenting with rapidly progressive (crescentic) IgA- predominant glomerulonephritis. BMJ Case Rep 14","DOI":"10.1136\/bcr-2021-242627"},{"key":"6113_CR29","first-page":"e10090","volume":"12","author":"A Klimko","year":"2020","unstructured":"Klimko A, Toma GA, Ion L, Mehedinti AM, Andreiana I (2020) A case report of generalized pustular psoriasis associated with IgA nephropathy. Cureus 12:e10090","journal-title":"Cureus"},{"key":"6113_CR30","unstructured":"Grandinetti V, Baraldi O, Comai G, Corradetti V, Aiello V, Bini C, et al. (2020) Renal dysfunction in psoriatic patients. G Ital Nefrol 37"},{"key":"6113_CR31","doi-asserted-by":"publisher","first-page":"e15433","DOI":"10.1097\/MD.0000000000015433","volume":"98","author":"L Zhang","year":"2019","unstructured":"Zhang L, Xue S, Yu J, Si H, Xu Y, Li J et al (2019) IgA nephropathy associated with erythrodermic psoriasis: a case report. Medicine (Baltimore) 98:e15433","journal-title":"Medicine (Baltimore)"},{"key":"6113_CR32","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1007\/s13730-019-00393-5","volume":"8","author":"M Ochi","year":"2019","unstructured":"Ochi M, Toyama T, Ando M, Sato K, Kamikawa Y, Sagara A et al (2019) A case of secondary IgA nephropathy accompanied by psoriasis treated with secukinumab. CEN Case Rep 8:200\u2013204","journal-title":"CEN Case Rep"},{"key":"6113_CR33","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1007\/s00108-018-0446-x","volume":"59","author":"K Herfurth","year":"2018","unstructured":"Herfurth K, Busch M, Gr\u00f6ne HJ, Wolf G (2018) Progressive renal insufficiency in a 55-year-old man with psoriasis. Internist (Berl) 59:1204\u20131207","journal-title":"Internist (Berl)"},{"key":"6113_CR34","doi-asserted-by":"publisher","first-page":"e79","DOI":"10.1111\/ijd.12622","volume":"54","author":"N Kluger","year":"2015","unstructured":"Kluger N, Du-Thanh A, Bessis D, Servel MF, Mourad G (2015) Psoriasis-associated IgA nephropathy under infliximab therapy. Int J Dermatol 54:e79-80","journal-title":"Int J Dermatol"},{"key":"6113_CR35","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1111\/j.1365-4632.2011.05302.x","volume":"52","author":"T Nakamura-Wakatsuki","year":"2013","unstructured":"Nakamura-Wakatsuki T, Kato Y, Sakurai K, Yamamoto T (2013) A case of severe erythrodermic psoriasis associated with IgA nephropathy. Int J Dermatol 52:1579\u20131581","journal-title":"Int J Dermatol"},{"key":"6113_CR36","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1111\/j.1525-1470.2008.00702.x","volume":"25","author":"A Wasilewska","year":"2008","unstructured":"Wasilewska A, Zoch-Zwierz WM, Tenderenda E, Szynaka B (2008) IgA nephropathy in a girl with psoriasis and seronegative arthritis. Pediatr Dermatol 25:408\u2013409","journal-title":"Pediatr Dermatol"},{"key":"6113_CR37","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1159\/000013388","volume":"18","author":"TS Ahuja","year":"1998","unstructured":"Ahuja TS, Funtanilla M, de Groot JJ, Velasco A, Badalamenti J, Wilson S (1998) IgA nephropathy in psoriasis. Am J Nephrol 18:425\u2013429","journal-title":"Am J Nephrol"},{"key":"6113_CR38","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1111\/j.1365-4362.1995.tb04400.x","volume":"34","author":"GL Perez","year":"1995","unstructured":"Perez GL, Agger WA, Abellera RM, Dahlberg P (1995) Pemphigus foliaceus coexisting with IgA nephropathy in a patient with psoriasis vulgaris. Int J Dermatol 34:794\u2013796","journal-title":"Int J Dermatol"},{"key":"6113_CR39","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.4049\/jimmunol.1800013","volume":"201","author":"JE Hawkes","year":"2018","unstructured":"Hawkes JE, Yan BY, Chan TC, Krueger JG (2018) Discovery of the IL-23\/IL-17 signaling pathway and the treatment of psoriasis. J Immunol 201:1605\u20131613","journal-title":"J Immunol"},{"key":"6113_CR40","doi-asserted-by":"crossref","unstructured":"Bhagat Singh AK, Jeyaruban AS, Wilson GJ, Ranganathan D (2019) Adalimumab-induced IgA nephropathy. BMJ case reports 12","DOI":"10.1136\/bcr-2018-226442"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-022-06113-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-022-06113-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-022-06113-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,10]],"date-time":"2022-06-10T11:13:30Z","timestamp":1654859610000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-022-06113-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,21]]},"references-count":40,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["6113"],"URL":"https:\/\/doi.org\/10.1007\/s10067-022-06113-2","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,21]]},"assertion":[{"value":"29 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The current study was approved by the Ethics Committee of the Second Hospital of Jilin University (No.2020101) and adhered to the Helsinki Declaration guidelines.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor of this journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"We did not use the services of external publishing agents.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publishing agency"}},{"value":"None.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}